Randox, Crumlin, UK, has released an analyte-specific reagent for adiponectin, in a format suited for use in automated clinical chemistry testing. Adiponectin is an adipokine (protein hormone) produced and secreted by adipose tissue. Acting as a messenger in communications among adipose tissue and metabolic organs, adiponectin suppresses the production of glucose in the liver by inhibiting the genes involved in glucose production and enhancing fatty acid oxidation in skeletal muscle.
Adiponectin has been identified as having pleiotropic functions associated with antiatherogenic, antidiabetic, antiinflammatory, and cardioprotective effects. Adiponectin levels inversely correlate with body mass index, glucose, insulin levels, insulin resistance, triglyceride levels, and visceral fat accumulation. Physiological functions of adiponectin have also been observed in inflammation and cardiovascular disease, especially in atherosclerosis.

The Randox adiponectin assay is formatted as a liquid, ready-to-use reagent that can be used on a wide range of clinical chemistry analyzers. The test’s latex-enhanced immunoturbidimetric method produces results in as little as 10 minutes. A measuring range of 0.32 μg/mL to 23.8 μg/mL allows for the detection of clinically important results. A correlation coefficient of r = 0.989 was found when the new Randox methodology was compared against the old Randox methodology. The reagent is for research use only.

For more information, visit Randox.